<SEC-DOCUMENT>0001213900-24-069975.txt : 20240816
<SEC-HEADER>0001213900-24-069975.hdr.sgml : 20240816
<ACCEPTANCE-DATETIME>20240816080002
ACCESSION NUMBER:		0001213900-24-069975
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20240816
FILED AS OF DATE:		20240816
DATE AS OF CHANGE:		20240816

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immuron Ltd
		CENTRAL INDEX KEY:			0001660046
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38104
		FILM NUMBER:		241214154

	BUSINESS ADDRESS:	
		STREET 1:		62 LYGON STREET
		STREET 2:		LEVEL 3
		CITY:			CARLTON, VICTORIA
		STATE:			C3
		ZIP:			3053
		BUSINESS PHONE:		61 03 9824 5254

	MAIL ADDRESS:	
		STREET 1:		62 LYGON STREET
		STREET 2:		LEVEL 3
		CITY:			CARLTON, VICTORIA
		STATE:			C3
		ZIP:			3053
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0211621-6k_immuron.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Form 6-K</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 UNDER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the Month of August 2024</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Commission File Number: 001-38104</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>IMMURON LIMITED</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Name of Registrant)</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Level 3, 62 Lygon Street, Carlton South,
Victoria, 3053, Australia</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive office)</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Form 20-F &#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">Indicate by check mark whether by furnishing the information contained
in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Yes &#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
&#9746;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If &ldquo;Yes&rdquo; is marked, indicate below the file number assigned
to the registrant in connection with Rule 12g3-2(b): 82-</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>IMMURON LIMITED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>EXPLANATORY NOTE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Immuron Limited (the &ldquo;Company&rdquo;) published
one announcement (the &ldquo;Public Notices&rdquo;) to the Australian Securities Exchange on August 16, 2024 titled:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">- &nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&ldquo;New US DoD Research Award to develop enhanced Travelan&rdquo;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A copy of the Public Notice is attached as an exhibit to this report
on Form 6-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This report on Form 6-K (including the exhibit
hereto) shall not be deemed to be &ldquo;filed&rdquo; for purposes of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange
Act&rdquo;) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be
expressly set forth by specific reference in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: bottom; width: 9%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B> <BR>
<B>Number</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 90%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="ea021162101ex99-1_immuron.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U STYLE="text-decoration: none">New US DoD Research Award to develop enhanced Travelan</U></FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.45in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMMURON LIMITED</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; text-indent: 0pt; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: August 16, 2024</FONT></TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="padding: 0pt; border-bottom: black 1.5pt solid; text-indent: 0pt; width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Phillip Hains</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phillip Hains</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Secretary</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea021162101ex99-1_immuron.htm
<DESCRIPTION>NEW US DOD RESEARCH AWARD TO DEVELOP ENHANCED TRAVELAN
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0 0pt 156.5pt"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 156.5pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex99-1_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 156.5pt">&nbsp;</P>

<P STYLE="font: bold 12pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">Immuron Announces New U.S. Department of Defense
Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan<SUP>&reg;</SUP></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><B><I>Highlights:</I></B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><B>$3.5 (USD $2.3) million funding for NMRC and WRAIR approved
by the U.S. Department of Defense to advance the development of Travelan.</B></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Melbourne, Australia, August 16, 2024:
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce
the funding of a new research agreement for the Naval Medical Research Command (NMRC), and Walter Reed Army Institute of Research (WRAIR)
Silver Spring, MD, USA.</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The focus of this new research agreement
is to develop an enhanced formulation of Travelan potentially expanding the coverage of the product as a therapeutic measure against endemic
military relevant diarrheal pathogens. This work will utilize the extensive experience of the US Department of Defense human infectious
disease vaccine programs and will target key protective antigens of the major enteric bacterial pathogens <I>Campylobacter, Shigella</I>
and Entertoxigenic <I>E. coli</I> strains not present in the current product formulation.</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Immuron will now negotiate a sub award
for collaboration with NMRC and WRAIR to advance this research.</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The U.S Department of Defense has recognized
the benefits of Immuron&rsquo;s technology platform and has an established long-standing relationship with Immuron to evaluate the commercial
over-the-counter bovine colostrum product Travelan for its specificity and effectiveness against diarrheal pathogens. As an extension
of the current Shigella (WRAIR), ETEC and Campylobacter (NMRC) research programs the goal of this award is to identify and define pathways
to formulate, characterize and perform pre-clinical testing of a military-relevant combined colostrum product.</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Infectious diarrhea is the most common
illness reported by travelers visiting developing countries and among US troops deployed overseas as indicated by the 2019 Department
of Defense (DoD) Infectious Disease Threats Prioritization Panel. The morbidity and associated discomfort stemming from diarrhea decreases
daily performance, affects judgment, decreases morale and declines operational readiness. The first line of treatment for infectious diarrhea
is the prescription of antibiotics. Unfortunately, in the last decade, several enteric pathogens have demonstrated increasing resistance
to commonly prescribed antibiotics. In addition, traveler&rsquo;s diarrhea is now recognized by the medical community to result in post-infectious
sequelae, including post-infectious irritable bowel syndrome (IBS) and several post-infectious autoimmune diseases. A preventative treatment
that defends against infectious enteric diseases is a high priority objective for the US Military.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This release has been authorised by the directors of Immuron Limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: center">- - - END - - -</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt"><B>&nbsp;</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex99-1_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 368.5pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 368.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0"><IMG SRC="ex99-1_003.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>COMPANY CONTACT:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>Steven Lydeamore</B> <BR>
Chief Executive Officer <BR>
Ph: +61
(0)3 9824 5254</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">info@immuron.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B>About Travelan<SUP>&reg;</SUP></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Travelan<SUP>&reg;</SUP> is an
orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers&rsquo; diarrhea, a digestive
tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan<SUP>&reg;</SUP> is a highly purified
tabletised preparation of hyper immune bovine antibodies and other factors, which when taken with meals bind to diarrhea-causing bacteria
and prevent colonization and the pathology associated with travelers&rsquo; diarrhea. In Australia, Travelan<SUP>&reg;</SUP> is a listed
medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travelers&rsquo; Diarrhea,
reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan<SUP>&reg;</SUP> is a licensed natural
health product (NPN 80046016) and is indicated to reduce the risk of Travelers&rsquo; Diarrhea. In the U.S., Travelan<SUP>&reg;</SUP>
is sold as a dietary supplement for digestive tract protection.</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B>About Travelers&rsquo; diarrhea</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Travelers&rsquo; diarrhea is a gastrointestinal
infection with symptoms that include loose, watery (and occasionally bloody) stools, abdominal cramping, bloating, and fever, Enteropathogenic
bacteria are responsible for most cases, with enterotoxigenic <I>Escherichia coli</I> (ETEC) playing a dominant causative role. Campylobacter
spp. are also responsible for a significant proportion of cases. The more serious infections with Salmonella spp. the bacillary dysentery
organisms belonging to Shigella spp. and Vibrio spp. (the causative agent of cholera) are often confused with travelers&rsquo; diarrhea
as they may be contracted while travelling and initial symptoms are often indistinguishable.</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B>About Immuron</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Immuron Limited (ASX: IMC, NASDAQ: IMRN),
is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for
the treatment of inflammatory mediated and infectious diseases.</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">For more information visit: http://www.immuron.com</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B>FORWARD-LOOKING STATEMENTS:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">This press release
may contain &ldquo;forward-looking statements&rdquo; within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our
growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are
based on management&rsquo;s current expectations and are subject to risks and uncertainties that could negatively affect our business,
operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently
anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic
agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting
and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our
ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional
funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings.
We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained
herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is
based, except as required by law.</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>Acknowledgment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">This work was supported by the U.S.
Army Medical Research and Development Command (USAMRDC), through the Joint Warfighter Medical Research Program (JWMRP) under Award Number
JW230174 funded for a total of $2,298,359. Opinions, interpretations, conclusions, and recommendations are those of the author and are
not necessarily endorsed by the Department of Defense. In conducting research using animals, the investigator(s) adhered to the laws of
the United States and regulations of the Department of Agriculture. In the conduct of research involving hazardous organisms or toxins,
the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 5.5pt; text-indent: 0.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;<IMG SRC="ex99-1_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5pt; text-align: justify; text-indent: 0.05pt"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.5pt; text-align: justify; text-indent: 0.05pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !" 0D# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#[@_X)Z?\
M!3[]M[XT_MM?!'X<_$KXU77B7P'X_P#&&J:=XA\*S>$_ ]CIS6,F@:[J<5O9
M7&F>&[+5K1;.XM+?[(R:DTH2)5N)+@%R_P#8NS*BL[LJ(JEF9B%55499F8X
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MGLI/BH_B[5_#FIR,&G-D+3Q_;:GHEP[Q1N9;2*(7,4.7"Q?(]?TC_P#!+/\
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M9M5JU:E.I*OA*-=J%7%8R%.M3IXVEC,)B<+4HN7L:V&Q-&I&<9'^@S7\T/\
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MGC:2=>G"=5KV=.KB:%;"5J-6M3A".(IRPV)E",ZL^?\ B=_X)0_\I#?V6_\
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M,Y0\,?&&479_V9%)KIS9-CHO_P EG(Z/%2*GXF>$$9:K^TIM_P#;N<8&2_\
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MO3IU+\-8/XTG:U"&UT]^OHC^%<VIN?'GB#RU)T[<28SX':]Z\]]5MT]66?\
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MJ^A1:UXJT"^T2TGUB_\ $WA6[M-/MSJ$4$EQ<36VG7T^V!)!'';.92FZ/?\
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M?8U*<Z<8RY5&/ZIT5\<_ C]N_P#9U_:/L_B#J'PNUSQ9?6GPQT >)O%LVO\
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M?MJ.J5[)^=EZGK5(Q_U%\*7RQN\Y\,TWRQNU[&KHW:[7DVSZB_X*H6=G9_\
M!/?]J)K:UMK7?X#LC(;>"*'>$\4Z 1O\M%+;<G&<XR<=:^8_V3?^"E'_  3^
M\!_LQ_ 3P7XU^._@?1_%OA;X3^"-"\2:5=^&_$TMUIVLZ9H5G::A9W$MOX9G
M@EF@N8I$>2*>5)&!<2-N)KZF_P""J^/^'>_[3^>G_""6?7_L:?#]<3^QM:_L
M@-^R?^SHWB>W_9L;Q$WP<\ -K3:Y#\+SK)U(^';$W9U0WZ_;3?F;=]J^U_Z1
MYV_SOWFZN#*EED_#FE_:N"S['T_]><;[*.18C#T*].?^K&!4I8B6)P&8J5)P
MM&$8PIM5-7-KW5WYJ\SAXBU?[*QN18"I_J/@O:RSS#XBO0J4_P#6;'<L</'#
M8_+W&JIWE.4IU(NFTE"+]Y^Z:!^TA^S]^TG\"OCGXA_9_P#'&A>.M'\.^"O&
M&CZ_?Z)IFI::EEJ-QX/U2\MK6==3TS3)I6DMOWJ-'')&%_C!XKY-_P""(FGV
M%S_P3O\ A9)<6-G.Y\6?%3+S6T$KG_BO]<7EG1F/RJJ\D_*JKT4 ?<>LS?!6
M/X._&?3_ (/2_"Z.%?AYXRN]9LOAK)X36(2OX7U:.WN=4MO"Y""1U5XX9KM-
MS*&5&(!%?G=_P1:^)_PT\+_\$_/AAI/B7XB>!?#VJ0>*?BA)/IFN>+M TG4(
M(Y?'FMS1/-97^H6]S$LL+I-&SQJ'B=)%)1E8XQI0GP'Q=#+,'FM*@N-.$)4,
M-C>;$YE3I?V+Q%=XB6$P=!2O-RDIPPM*"A*FM6G*6\JLX<=<)3S/%Y55K_ZG
M<71KXG!<N&RZI5_MCAZRP\<5BZ\HV@HIPGB:LW.-1Z)J,>&_X*W_  V\*?LX
M#X'_ +>?PCTC3/ 'Q2^%_P 8_"VB^+=1\+V,&C_\)SX/UV/4KB\TOQ';V$<-
MOJ08:=<:9+//#)=3Z?K5Y;2RM&L+0?M?_P )?%_SZG_OL_\ Q%?AQ_P4<^,?
M@S]N#QY\"OV"/V=M=TCXJZIK?Q9T#QQ\:?$7A&Y37?#'@3P3X6CGCO?MWB'3
MFN-(DNDLM7O=0N8HKB:&&6VTS3Y9H]0U.V@'[L?\(SI__33\U_\ B:PXF56C
MPEP+0SV.(6<PI\15*5/%>T684>':V88%Y+#$QKVQ5.A+$0S:KEU/$*+6%G.5
M"$,/.FGKPU*C6XKXYKY'*A+)Y5.':52IA'3> J\0T<OQRSF>'E1OA:E>-">4
MTLPJ89R3Q4(QKSEB(3MT5%%%?FY^CA1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %9'B  Z#K8(!!TC4@01D$&SF!!!X((X(/6BBKI_Q*?\ U\I_
M^G($5/X=3_!/_P!(F?P :MX4\++JFI!?#6@*/M][P-&TX#_CYE':V] !] !7
MZ??\$F-"T2Q^-/QHDLM'TJS>3]FCXF0R/:Z?:6[R0R7.@;XG:*%"T;[5WQL2
MK8&0<"BBO[CXVJU7P9GB=6JT\NI73JU&G_MF4[IU&GLMT]D?Q'P52I+C+)&J
M5)-9A5LU3IIK_9,UV:IIK=[-;GW]^SUI6EI_P1C^(FFIIM@FG3>#/BGYU@MG
M;K92^=K$KS>9:B,02>:Y+2[HSYC$LV22:^[/A%I6ES_\$X?">CSZ;83:2_[*
M3VCZ7+9V\FG/:CX=W*BV:Q>-K9K<* !"8C&   N ***_G7B><_:YL^>=_P#B
M+6(G?GG?G^HX/W[\U^?1>_?GT7O:(_H7AB$/992N2%O^(48:%N2-N3Z_C?<M
MRVY-7[MN7^Z<5_P3)TO3-+_8!^&MMIFG6.G6\VF?$*YF@L;2WM(9;B?Q3XD\
M^>2*WCC1YIL#S964O)@;V.!7@/[$.G:?!_P3:_:%LH+&SALI=3_::22TBM8(
M[61'L-1C=7MT01.KQ@1LK(0R *05 %%%&.G-XOCEN<VY>(_#LI-SDW*2SK-+
M2DW)N4ETE)MKHT/!P@L+P0E""4?#KB.,4HQ2C%Y)E=XQ2BE&+ZQBE%]4SZH_
MX)AVEK9?L/? VVLK:WM+:/2O$1CM[6&.W@0OXOUZ1RD42I&N]V9VVJ-SLS')
M))\9\7Z?8-_P6"^%6I-8V;:BG[+FLVZ7YMH3>I!_:'C@^0MT4\]8<R2'RQ($
MR[G;\S9**X82E_K?XBOFE>65<>J3YI7DI3I\RD^:\E+JI-WZW.Z48_ZH^'BY
M8VCF? KBN6-HN-.IRN*Y;1<?LN*5NECZ+_X**VMK??L4_M!6E[;6]Y:S^#(E
MFMKJ&.XMYE&NZ0P66&57CD4, V'4C(!QD"OXKW\*>%U8A?#>@  X &CZ< !Z
M "VP***_5_ JI4CPYFZC4G%/.FVHSG%7_L_#*]HSBKVTO:]NI^4^.5.G+B+*
M'*$)/^Q;7E"$G;^T,0[7E"3M?6U[7UM<_;G_ ((\Z/I%CX?_ &PULM*TVS6X
M^%4$5PMK8VMNL\?]G^)/W<PAB02I\[_(X9?G;CYCG\2#X2\*B2-1X9\/A2T6
M5&C::%.67.0+;!SWR.>]%%?:9!5JKC+CYJK43E4X9<FJE1.5LDKI7:J)NRT5
MV[+166A\;G]*D^#N DZ=-I4N)K)TZ;2OG-%NR=-I7>KLE=ZN[U/[$_\ @FK\
M-OAUX+_9XT#6?!W@'P5X3U?Q#&C:_JOAGPKH6@ZEKC0(@A;6+[2["UNM3:$
M"(WLLYC PA%?H?117\C\65:M;B7/*E:K5K5'F>+BZE:I4JS<8U91BG.K4JS:
MC%*,4YM1BE&*C%**_K/A6E2H\-Y)3HTJ5&FLMPC4*-.G2@G*C&4FH4J=*"<I
--RDU!.4FY2<I-R?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_002.jpg
M_]C_X  02D9)1@ ! 0   0 !  #__@ ?0V]M<')E<W-E9"!B>2!J<&5G+7)E
M8V]M<')E<W/_VP"$  0$! 0$! 0$! 0&!@4&!@@'!P<'" P)"0D)"0P3# X,
M# X,$Q$4$ \0%!$>%Q45%QXB'1L=(BHE)2HT,C1$1%P!! 0$! 0$! 0$! 8&
M!08&" <'!P<(# D)"0D)#!,,#@P,#@P3$100#Q 4$1X7%147'B(=&QTB*B4E
M*C0R-$1$7/_" !$( &(#10,!(@ "$0$#$0'_Q  =  $  00# 0
M    !@0%!P@! @,)_]H " $!     -_@
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MQCN8^3LH]EY??@JZF*.,  ]OT[MNW9OW[+#P ^&@  E;?==?ITZM5^K7KL
M /R/GAZE*4[9SG;=;;(     ?/P        __\0 ' $!  (# 0$!
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M;A'U_P"W(D 23%'XECWC5V;E)I)2)!.TUEJ8B+8S>)&XEJ7!C94C"V$-J2N
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ML54LJ*6=@?%*PYM<"J"N;7,J:BF,SA'R/% "2>9V>1X?<H:VH=5QOE8:<,(
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MD='44X/R6S$A[>[,?;FIBB9VR/#1XE7^D.72(7\J?]/-"LJNPQQ!H_U"U6$
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MPR19&*-AX@UQ\S^Q1O:&,<8@?DAWV+&>Y2S3R^_Z<\$+"]W7U-5)/#./?O\
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M@VK"EGT,&U84L^A@VK"EGT,&U84L^A@VK"EGT,&U84L^A@VK"EGT,&U?_\0
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MWL%HW[1C"O+(9 GU0:-\[6)LF0$&;K2^>W-07C06MW:A 1/T<MGET?@ !/8
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M:!/O:I>*]<EZ7(0?T(!4NKZM/\)?SG[9'LQ3232=^5V]9B:Y3\IKDKE%<HK
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1@[5@[5@[5@[5@[5@[?Q;_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ex99-1_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  L +,# 2(  A$! Q$!_\0
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M<2:1>6,EQ^^:2O'_ /@JU!%<?\$]OVG4FCCE5/!>DSJLB*X66W\:>&)X9%#
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MK8S'>QJ8G&8R7+0HTHQ<I3J1BKN%&C+^8K_@G\P7_@N3^U>#_'J/[32#Z_\
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MO(?$^M^)VLV'W[+^W;[5/L;GYGM5B=@&)%>H_LG7_P#P1@_8XO\ _A(/A?\
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MA)"VQ)M9^)VJ3ZG>V#L)-_@"Y)C9+:8#3\"?O/CQ_P $3/, ??\ LD?&+?N
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M**?L,ZI(\RW&F?#7]JJ.!$:,0NMYX=\$12^<K1L[$*H*%)(\,/FW D'\]O\
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K!K9UB8UL'E^#PU6-!J="%2AAX4Y4Z$ZJ]K.C2:5&C.I:<J5"E*23E:/_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
